Industry Spotlight

Patient treatment commences in Cynata clinical trial

18 May 2017 via Biotech Dispatch: Australian stem cell and regenerative medicine company, Cynata Therapeutics (ASX:CYP), has announced the first patient has been treated with CYP-001, its first mesenchymal stem cell (MSC) product, in its Phase 1 clinical trial in patients with steroid-resistant acute graft versus host disease (GvHD). 

Read more in Biotech Dispatch.